Valeant Pharmaceuticals International, Inc. (NYSE:VRX) dropped -0.33% and closed the trade at $ 27.28. The company recorded a trading capacity of 10.48 million shares below its three months average daily volume of 27.14 million shares. During the last trade, shares reached to high price of $27.45 and touched the low price of $26.77. The stock’s 50-day moving average is noted at $27.01 and its 200-day moving average is stands at $30.50.
Additionally, the company has EPS of -2.93. The company has market capitalization of $9.48B.
Currently Valeant Pharmaceuticals International, Inc. (VRX) captured an average recommendation of “ Hold ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “6″ Analysts”. “3” rated “Sell” for the company. “11” said the company as a “Hold”. Overweight rating was given by “1” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $39.21 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $81.00 however minimum price target advised by analysts is $16.00. The Median price target for the stock is measured at $35.50.
Presently, Analysts decided consensus EPS estimate of $1.79 for present quarter and one month ago projected EPS estimate was at $1.80. If we take a look at back 3 month ago, consensus EPS estimate was $1.79.
A current consensus EPS estimate for next quarter is at $2.07 and 3 month ago EPS forecast was $1.99. Have a look at back 1 month ago, consensus EPS forecast was seen at $2.07.
For current fiscal year, most recent EPS estimate is set at $6.56 based on Analyst consensus and three month ago consensus EPS opinions was at $6.68. During period one month ago, consensus EPS forecast was decided at $6.56.
A current consensus EPS projection for next fiscal year is observed at $7.70 and one month ago consensus EPS forecast was at $7.71. Take a look at back three month ago, consensus EPS estimate opinions was decided at $7.90 by analysts.
One Month ago, the stock has gained consensus mean rating of Hold based on the analysis of brokerage analyst firms polled. 5 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 1. 12 advised the “Hold” rating about this stock. 3 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Hold derived from brokerage firms, according to FactSet. 6 said a “Buy Rating” and 1 announced “Overweight Rating”. 10 advised “Hold Rating” regarding the stock. 3 announced “Sell Rating” and 1 disclosed “Underweight Rating”.